MENTOR, Ohio, July 24 /EMWNews/ -- STERIS Corporation

(NYSE: STE) today announced that its Board of Directors has authorized a

33% increase in its quarterly dividend to $0.08 per common share. The

dividend is payable September 11, 2008 to shareholders of record at the

close of business on August 14, 2008.

    About STERIS



    The mission of STERIS Corporation is to provide a healthier today and

safer tomorrow through knowledgeable people and innovative infection

prevention, decontamination and health science technologies, products and

services. The Company's more than 5,000 dedicated employees around the

world work together to supply a broad array of solutions by offering a

combination of equipment, consumables and services to healthcare,

pharmaceutical, industrial and government customers. The Company is listed

on the New York Stock Exchange under the symbol STE. For more information,

visit http://www.steris.com .



    This news release may contain statements concerning certain trends,

expectations, forecasts, estimates, or other forward-looking information

affecting or relating to the Company or its industry that are intended to

qualify for the protections afforded "forward-looking statements" under the

Private Securities Litigation Reform Act of 1995 and other laws and

regulations. Forward-looking statements speak only as to the date of this

report, and may be identified by the use of forward-looking terms such as

"may," "will," "expects," "believes," "anticipates," "plans," "estimates,"

"projects," "targets," "forecasts," "confidence," and "seeks," or the

negative of such terms or other variations on such terms or comparable

terminology. Many important factors could cause actual results to differ

materially from those in the forward-looking statements including, without

limitation, disruption of production or supplies, changes in market

conditions, political events, pending or future claims or litigation,

competitive factors, technology advances, and changes in government

regulations or the application or interpretation thereof. Other risk

factors are described in the Company's Form 10-K and other securities

filings. Many of these important factors are outside STERIS's control. No

assurances can be provided as to any future dividend payment or other

financial results. Unless legally required, the Company does not undertake

to update or revise any forward-looking statements even if events make

clear that any projected results, express or implied, will not be realized.

Other potential risks and uncertainties that could cause actual results to

differ materially from those in the forward-looking statements include,

without limitation, (a) the potential for increased pressure on pricing

that leads to erosion of profit margins, (b) the possibility that market

demand will not develop for new technologies, products or applications, or

the Company's business initiatives will take longer, cost more or produce

lower benefits than anticipated, (c) the possibility that application of or

compliance with laws, court rulings, regulations, regulatory actions,

including without limitation the previously disclosed FDA warning letter,

certifications or other requirements or standards may delay or prevent new

product introductions, affect the production and marketing of existing

products, or otherwise affect Company performance, results, or value, (d)

the potential of international unrest or effects of fluctuations in

currencies, tax assessments or rates, raw material costs, benefit or

retirement plan costs, or other regulatory compliance costs, (e) the

possibility of reduced demand, or reductions in the rate of growth in

demand, for the Company's products and services, and (f) the possibility

that anticipated cost savings may not be achieved, or that transition,

labor, competition, timing, execution, regulatory, governmental, or other

issues or risks associated with the matters described in this release may

adversely impact Company performance, results, or value.